The bispecific antibody was approved for certain patients whose bile duct cancer harbors gene fusions that involve the neuregulin 1 gene. The U.S. Food and Drug Administration (FDA) approved zenocutuzumab-zbco (Bizengri) for the treatment...
Findings signal targeted therapy effectiveness in pancreatic cancer, and new insights into the thymus’s role in cancer and health.
At the AACR Annual Meeting 2026, National Cancer Institute Director Anthony Letai offered insights into what NCI considers to be priorities.
Vepdegestrant is the first PROTAC approved for any cancer indication. The U.S. Food and Drug Administration (FDA) approved vepdegestrant (Veppanu) for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced...
Heart, kidney and metabolic conditions may be linked to higher cancer risk, and a pooled cord blood therapy was found safe and similarly effective as traditional transplant in blood cancers.
In April 2026, AACR's journals editors highlighted studies on cancer survivors taking GLP-1 agonists, an immunotherapy-boosting bacteria, and more.
Injecting immunotherapy directly into precancerous oral lesions may be an effective way to prevent progression to cancer without surgery.
People with alveolar soft part sarcoma can receive immunotherapy treatment for an extended period without long-term side effects.
Rates of treatment-related leukemia rise as more people survive cancer, and cancer rates are higher in people who have never been married.
Here’s what these AACR Runners for Research had to say as they prepare to pound some pavement and raise money at the AACR Annual Meeting 2026.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More